The global antinuclear antibody test market size is expected to reach USD 2.36 billion by 2025,
according to a new report by Grand View Research, Inc. It is anticipated to
expand at a CAGR of 12.5% over the forecast period. Rising adoption of ANA test
coupled with government initiatives to treat autoimmune disorders is likely to
drive the market. Furthermore, rising incidence of autoimmune disorders is
projected to fuel the growth.
Antinuclear Antibody (ANA) testing is an
important tool to diagnose and manage autoimmune diseases such as Systemic
Lupus Erythematosus (SLE) and rheumatoid arthritis. According to the Lupus
Foundation of America, at least 5 million people globally and around 1.5
million people in U.S. have a form of lupus. Around 16,000 new cases are
registered every year. The disease mostly affects women of childbearing age.
SLE accounts for almost 70% of all cases of lupus. The high prevalence of autoimmune
disorders is one of the factors driving the market.
Extension of ANA from a test for SLE to a
test for any autoimmune diseases has boosted the usage of antinuclear antibody
testing. An increase in ANA demand may also be due to the factors such as
expanded role of primary care physicians in healthcare delivery systems. In
addition, rising R&D activities and government initiatives regarding early
diagnosis of autoimmune disorders have triggered the demand for ANA tests.
Access Research Report of Antinuclear
Antibody Test Market @ https://www.grandviewresearch.com/industry-analysis/antinuclear-antibody-ana-test-market
Further key findings from the study suggest:
· Reagents and assay kits was the largest
segment in 2017. It is likely to witness fastest growth over the forecast
period due to wide usage and rise in a number of reagent rental agreements
· Immunofluorescence assay led the market in
terms of market share in 2017 owing to superior sensitivity compared to other
available techniques
· ELISA is expected to be the fastest growing
segment over the forecast period. Increasing adoption of these tests is
attributed to easy automation and handling without high level of operator skill
· Rheumatoid arthritis segment is projected
to hold largest market share, mainly due to high prevalence of the disease
· North America was the largest region in
terms of revenue in 2017, followed by Europe. Both are the most
well-established regions in terms of the adoption of ANA testing and make up
most of the existing market
· Asia Pacific is likely to be the fastest
growing region over the forecast period due to unmet clinical needs and need
for better diagnosis. Rising government initiatives and clinical research
activities for advanced diagnostics are expected to further fuel growth
· Key players operating in the antinuclear
antibody test market are Thermo Fisher Scientific Inc.; Alere Inc.; Bio-Rad
Laboratories; Trinity Biotech PLC; Zeus Scientific, Inc.; Inova Diagnostics;
Immuno Concepts; Erba Diagnostics, Inc.; Euroimmun AG; and Antibodies Inc.
· Key companies are adopting R&D,
geographic expansion, and collaborations to gain market share.
Grand View Research has segmented the
global antinuclear antibody test market on the basis of product, technique,
application, end use, and region:
Antinuclear Antibody Test Product Outlook
(Revenue, USD Million, 2014 - 2025)
·
Reagents & Assay Kits
·
Systems
·
Software & Services
Antinuclear Antibody Test Technique Outlook
(Revenue, USD Million, 2014 - 2025)
·
ELISA
·
Immunofluorescence Assay
·
Multiplex Assay
Antinuclear Antibody Test Application
Outlook (Revenue, USD Million, 2014 - 2025)
·
Rheumatoid Arthritis
·
Systemic Lupus Erythematosus
·
Sjogren’s Syndrome
·
Scleroderma
·
Others
Antinuclear Antibody Test End-use Outlook
(Revenue, USD Million, 2014 - 2025)
·
Hospitals
·
Clinical Laboratories
·
Physician Office Laboratories
·
Others
Antinuclear Antibody Test Regional Outlook
(Revenue, USD Million, 2014 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
U.K.
o
Germany
·
Asia Pacific
o
Japan
o
China
o
India
·
Latin America
o
Brazil
o
Mexico
·
MEA
o
South Africa
Access Press Release of Antinuclear Antibody Test
Market@ https://www.grandviewresearch.com/press-release/global-antinuclear-antibody-ana-test-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
